AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Science Translational Medicine

Volumn 7, Issue 314, 2015, Pages

  Hong, David ^a   Kurzrock, Razelle ^b   Kim, Youngsoo ^c   Woessner, Richard ^d   Younes, Anas ^e   Nemunaitis, John ^f   Fowler, Nathan ^a   Zhou, Tianyuan ^c   Schmidt, Joanna ^c   Jo, Minji ^c   Lee, Samantha J ^c   Yamashita, Mason ^c   Hughes, Steven G ^c   Fayad, Luis ^a   Piha Paul, Sarina ^a   Nadella, Murali V P ^d   Mohseni, Morvarid ^d   Lawson, Deborah ^d   Reimer, Corinne ^d   Blakey, David C ^d   Xiao, Xiaokun ^c   Hsu, Jeff ^c   Revenko, Alexey ^c   Monia, Brett P ^c   MacLeod, A Robert ^c   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d ASTRAZENECA   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Mary Crowley Cancer Research Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; AZD 9150; CRIZOTINIB; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZD9150; OLIGONUCLEOTIDE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; LUNG CANCER; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WEAKNESS; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SCID MOUSE; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947724597     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac5272     Document Type: Article

References (60)

1. L. Chin, J. W. Gray, Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008).
2. H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, M. D. Johnson, Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc. Natl. Acad. Sci. U.S.A. 107, 2183-2188 (2010).
3. Y. Yang, S. J. Adelstein, A. I. Kassis, Integrated bioinformatics analysis for cancer target identification. Methods Mol. Biol. 719, 527-545 (2011).
4. I. B. Weinstein, A. Joe, Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
5. D. Torti, L. Trusolino, Oncogene addiction as a foundational rationale for targeted anticancer therapy: Promises and perils. EMBO Mol. Med. 3, 623-636 (2011).
6. R. S. Herbst, G. Giaccone, J. H. Schiller, R. B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J. A. Reeves, M. K. Wolf, A. D. Krebs, S. D. Averbuch, J. S. Ochs, J. Grous, A. Fandi, D. H. Johnson, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
7. A. Quintás-Cardama, H. Kantarjian, J. Cortes, Imatinib and beyond-Exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol. 6, 535-543 (2009).
8. A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, J. Gainor, J. A. Engelman, G. I. Shapiro, D. B. Costa, S.-H. I. Ou, M. Butaney, R. Salgia, R. G. Maki, M. Varella-Garcia, R. C. Doebele, Y.-J. Bang, K. Kulig, P. Selaru, Y. Tang, K. D. Wilner, E. L. Kwak, J. W. Clark, A. J. Iafrate, D. R. Camidge, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
9. F. J. Raal, R. D. Santos, D. J. Blom, A. D. Marais, M.-J. Charng, W. C. Cromwell, R. H. Lachmann, D. Gaudet, J. L. Tan, S. Chasan-Taber, D. L. Tribble, J. D. Flaim, S. T. Crooke, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebocontrolled trial. Lancet 375, 998-1006 (2010).
10. F. Saad, S. Hotte, S. North, B. Eigl, K. Chi, P. Czaykowski, L. Wood, M. Pollak, S. Berry, J.-B. Lattouf, S. D. Mukherjee, M. Gleave, E. Winquist; Canadian Uro-Oncology Group, Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after firstline docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17, 5765-5773 (2011).
11. T. M. Wheeler, A. J. Leger, S. K. Pandey, A. R. MacLeod, M. Nakamori, S. H. Cheng, B. M. Wentworth, C. F. Bennett, C. A. Thornton, Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115 (2012).
12. H. R. Büller, C. Bethune, S. Bhanot, D. Gailani, B. P. Monia, G. E. Raskob, A. Segers, P. Verhamme, J. I. Weitz; FXI-ASO TKA Investigators, Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372, 232-240 (2015).
13. D. Gaudet, D. Brisson, K. Tremblay, V. J. Alexander, W. Singleton, S. G. Hughes, R. S. Geary, B. F. Baker, M. J. Graham, R. M. Crooke, J. L. Witztum, Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371, 2200-2206 (2014).
14. P. P. Seth, A. Siwkowski, C. R. Allerson, G. Vasquez, S. Lee, T. P. Prakash, E. V. Wancewicz, D. Witchell, E. E. Swayze, Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
15. S. Murray, D. Ittig, E. Koller, A. Berdeja, A. Chappell, T. P. Prakash, M. Norrbom, E. E. Swayze, C. J. Leumann, P. P. Seth, TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-A comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res. 40, 6135-6143 (2012).
16. M. Furqan, A. Akinleye, N. Mukhi, V. Mittal, Y. Chen, D. Liu, STAT inhibitors for cancer therapy. J. Hematol. Oncol. 6, 90 (2013).
17. M. E. Østergaard, A. L. Southwell, H. Kordasiewicz, A. T. Watt, N. H. Skotte, C. N. Doty, K. Vaid, E. B. Villanueva, E. E. Swayze, C. F. Bennett, M. R. Hayden, P. P. Seth, Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 41, 9634-9650 (2013).
18. B. P. Monia, J. F. Johnston, T. Geiger, M. Muller, D. Fabbro, Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2, 668-675 (1996).
19. S. Akhtar, I. F. Benter, Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117, 3623-3632 (2007).
20. E. Koller, T. M. Vincent, A. Chappell, S. De, M. Manoharan, C. F. Bennett, Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795-4807 (2011).
21. C. A. Stein, J. B. Hansen, J. Lai, S. Wu, A. Voskresenskiy, A. Høg, J. Worm, M. Hedtjärn, N. Souleimanian, P. Miller, H. S. Soifer, D. Castanotto, L. Benimetskaya, H. Ørum, T. Koch, Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3 (2010).
22. D. B. Rozema, D. L. Lewis, D. H. Wakefield, S. C. Wong, J. J. Klein, P. L. Roesch, S. L. Bertin, T. W. Reppen, Q. Chu, A. V. Blokhin, J. E. Hagstrom, J. A. Wolff, Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 104, 12982-12987 (2007).
23. J. E. Zuckerman, C.H. J. Choi, H. Han, M. E. Davis, Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basementmembrane. Proc. Natl. Acad. Sci. U.S.A. 109, 3137-3142 (2012).
24. M. Hedvat, D. Huszar, A. Herrmann, J. M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C. M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z. A. Cao, H. Yu, R. Jove, M. Zinda, The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
25. A. Zamo, R. Chiarle, R. Piva, J. Howes, Y. Fan, M. Chilosi, D. E. Levy, G. Inghirami, Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21, 1038-1047 (2002).
26. A. Scuto, M. Kujawski, C. Kowolik, L. Krymskaya, L. Wang, L. M. Weiss, D. DiGiusto, H. Yu, S. Forman, R. Jove, STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 71, 3182-3188 (2011).
27. C. R. Taylor, R. M. Levenson, Quantification of immunohistochemistry-Issues concerning methods, utility and semiquantitative assessment II. Histopathology 49, 411-424 (2006).
28. F. Varghese, A. B. Bukhari, R. Malhotra, A. De, IHC Profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLOS One 9, e96801 (2014).
29. R. Z. Yu, J. S. Grundy, S. P. Henry, T.-W. Kim, D. A. Norris, J. Burkey, Y. Wang, A. Vick, R. S. Geary, Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2′-O-(2-methoxyethyl) modifications. Mol. Ther. Nucleic Acids 4, e218 (2015).
30. M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, T. A. Waldmann, Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 108, 705-710 (2006).
31. L. Song, B. Rawal, J. A. Nemeth, E. B. Haura, JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol. Cancer Ther. 10, 481-494 (2011).
32. B. D. Looyenga, D. Hutchings, I. Cherni, C. Kingsley, G. J. Weiss, J. P. MacKeigan, STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLOS One 7, e30820 (2012).
33. T. Murakami, N. Takigawa, T. Ninomiya, N. Ochi, M. Yasugi, Y. Honda, T. Kubo, E. Ichihara, K. Hotta, M. Tanimoto, K. Kiura, Effect of AZD1480 in an epidermal growth factor receptordriven lung cancer model. Lung Cancer 83, 30-36 (2014).
34. S. A. Burel, S.-R. Han, H.-S. Lee, D. A. Norris, B.-S. Lee, T. Machemer, S.-Y. Park, G. He, Y. Kim, A. R. Macleod, B. P. Monia, S. Lio, S. P. Henry, T. Zhou, T.-W. Kim, Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23, 213-227 (2013).
35. V. N. Ngo, R. M. Young, R. Schmitz, S. Jhavar, W. Xiao, K.-H. Lim, H. Kohlhammer, W. Xu, Y. Yang, H. Zhao, A. L. Shaffer, P. Romesser, G. Wright, J. Powell, A. Rosenwald, H. K. Muller-Hermelink, G. Ott, R. D. Gascoyne, J. M. Connors, L. M. Rimsza, E. Campo, E. S. Jaffe, J. Delabie, E. B. Smeland, R. I. Fisher, R. M. Braziel, R. R. Tubbs, J. R. Cook, D. D. Weisenburger, W. C. Chan, L. M. Staudt, Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
36. D. C. Talbot, M. Ranson, J. Davies, M. Lahn, S. Callies, V. André, S. Kadam, M. Burgess, C. Slapak, A. L. Olsen, P. J. McHugh, J. S. de Bono, J. Matthews, A. Saleem, P. Price, Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: A proof-of-concept, first-inhuman dose study. Clin. Cancer Res. 16, 6150-6158 (2010).
37. K. Kirito, M. Osawa, H. Morita, R. Shimizu, M. Yamamoto, A. Oda, H. Fujita, M. Tanaka, K. Nakajima, Y. Miura, K. Ozawa, N. Komatsu, A functional role of Stat3 in in vivo megakaryopoiesis. Blood 99, 3220-3227 (2002).
38. C. Mantel, S. Messina-Graham, A. Moh, S. Cooper, G. Hangoc, X.-Y. Fu, H. E. Broxmeyer, Mouse hematopoietic cell-targeted STAT3 deletion: Stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood 120, 2589-2599 (2012).
39. L. Visconti, K. Nelissen, L. Deckx, M. van den Akker, W. Adriaensen, L. Daniels, C. Matheï, L. Linsen, N. Hellings, P. Stinissen, F. Buntinx, Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients. Biomark. Med. 8, 297-306 (2014).
40. J. F. Seymour, M. Talpaz, F. Cabanillas, M. Wetzler, R. Kurzrock, Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J. Clin. Oncol. 13, 575-582 (1995).
41. T. R. Faruqi, D. Gomez, X. R. Bustelo, D. Bar-Sagi, N. C. Reich, Rac1 mediates STAT3 activation by autocrine IL-6. Proc. Natl. Acad. Sci. U.S.A. 98, 9014-9019 (2001).
42. K. N. Chi, S. J. Hotte, E. Y. Yu, D. Tu, B. J. Eigl, I. Tannock, F. Saad, S. North, J. Powers, M. E. Gleave, E. A. Eisenhauer, Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 4247-4254 (2010).
43. M. Sen, S. M. Thomas, S. Kim, J. I. Yeh, R. L. Ferris, J. T. Johnson, U. Duvvuri, J. Lee, N. Sahu, S. Joyce, M. L. Freilino, H. Shi, C. Li, D. Ly, S. Rapireddy, J. P. Etter, P.-K. Li, L. Wang, S. Chiosea, R. R. Seethala, W. E. Gooding, X. Chen, N. Kaminski, K. Pandit, D. E. Johnson, J. R. Grandis, First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discov. 2, 694-705 (2012).
44. M. Sen, K. Paul, M. L. Freilino, H. Li, C. Li, D. E. Johnson, L. Wang, J. Eiseman, J. R. Grandis, Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol. Med. 20, 46-56 (2014).
45. J. C. Bendell, D. S. Hong, H. A. BurrisIII, A. Naing, S. F. Jones, G. Falchook, P. Bricmont, A. Elekes, E. P. Rock, R. Kurzrock, Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. 74, 125-130 (2014).
46. A. L. Wong, R. A. Soo, D. S. Tan, S. C. Lee, J. S. Lim, P. C. Marban, L. R. Kong, Y. J. Lee, L. Z. Wang, W. L. Thuya, R. Soong, M. Q. Yee, T. M. Chin, M. T. Cordero, B. R. Asuncion, B. Pang, S. Pervaiz, J. L. Hirpara, A. Sinha, W. W. Xu, M. Yuasa, T. Tsunoda, M. Motoyama, T. Yamauchi, B. C. Goh, Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. 26, 998-1005 (2015).
47. C. L. Yu, D. J. Meyer, G. S. Campbell, A. C. Larner, C. Carter-Su, J. Schwartz, R. Jove, Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83 (1995).
48. D. DeArmond, M. G. Brattain, J. Milburn Jessup, J. Kreisberg, S. Malik, S. Zhao, J. W. Freeman, Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22, 7781-7795 (2003).
49. H. Yoshikawa, K. Matsubara, G.-S. Qian, P. Jackson, J. D. Groopman, J. E. Manning, C. C. Harris, J. G. Herman, SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28, 29-35 (2001).
50. E. C. Brantley, L. Burton Nabors, G. Yancey Gillespie, Y.-H. Choi, C. A. Palmer, K. Harrison, K. Roarty, E. N. Benveniste, Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression. Clin. Cancer Res. 14, 4694-4704 (2008).
51. P. Koppikar, N. Bhagwat, O. Kilpivaara, T. Manshouri, M. Adli, T. Hricik, F. Liu, L. M. Saunders, A. Mullally, O. Abdel-Wahab, L. Leung, A. Weinstein, S. Marubayashi, A. Goel, M. Gönen, Z. Estrov, B. L. Ebert, G. Chiosis, S. D. Nimer, B. E. Bernstein, S. Verstovsek, R. L. Levine, Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159 (2012).
52. D. J. Gough, A. Corlett, K. Schlessinger, J. Wegrzyn, A. C. Larner, D. E. Levy, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324, 1713-1716 (2009).
53. H.-J. Lee, G. Zhuang, Y. Cao, P. Du, H.-J. Kim, J. Settleman, Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207-221 (2014).
54. R. Chiarle, W. J. Simmons, H. Cai, G. Dhall, A. Zamo, R. Raz, J. G. Karras, D. E. Levy, G. Inghirami, Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623-629 (2005).
55. D. S. Hong, R. Kurzrock, Y. Oh, J. Wheler, A. Naing, L. Brail, S. Callies, V. André, S. K. Kadam, A. Nasir, T. R. Holzer, F. Meric-Bernstam, M. Fishman, G. Simon, A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 17, 6582-6591 (2011).
56. M. A. Villalona-Calero, P. Ritch, J. A. Figueroa, G. A. Otterson, R. Belt, E. Dow, S. George, J. Leonardo, S. McCachren, G. L. Miller, M. Modiano, M. Valdivieso, R. Geary, J. W. Oliver, J. Holmlund, A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-α, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10, 6086-6093 (2004).
57. Y. Minegishi, M. Saito, S. Tsuchiya, I. Tsuge, H. Takada, T. Hara, N. Kawamura, T. Ariga, S. Pasic, O. Stojkovic, A. Metin, H. Karasuyama, Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058-1062 (2007).
58. J. M. Leeds, M. J. Graham, L. Truong, L. L. Cummins, Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235, 36-43 (1996).
59. T. P. Prakash, M. J. Graham, J. Yu, R. Carty, A. Low, A. Chappel, K. Schmidt, C. Zhao, M. Aghajan, H. F. Murray, S. Riney, S. L. Booten, S. F. Murray, H. Gaus, J. Crosby, W. F. Lima, S. Guo, B. P. Monia, E. E. Swayze, P. P. Seth, Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796-8807 (2014).
60. B. F. Baker, S. S. Lot, T. P. Condon, S. Cheng-Flournoy, E. A. Lesnik, H. M. Sasmor, C. F. Bennett, 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000 (1997).